论文部分内容阅读
目的探讨促红细胞生成素(EPO)在防治早产儿脑损伤中的作用。方法早产儿30例。男23例,女7例;随机分为常规治疗组、EPO治疗组,各15例。EPO治疗组于生后即开始予EPO治疗。所有患儿随诊至1岁,定期行脑电图、脑干诱发电位(ABR)检查及头颅B超等影像学检查,并于纠正胎龄40周行新生儿行为神经检测(NBNA)。结果1.EPO治疗组NBNA评分正常者占73.33%,明显高于常规治疗组(26.67%),差异有显著性(P<0.05);2.纠正胎龄1个月时二组患儿ABR异常率比较差异无统计学意义(P>0.05),随访至3~6个月时,EPO治疗组ABR异常率明显小于常规治疗组(P<0.05)。EPO治疗组后期ABR的异常程度较前明显减轻。结论早期使用EPO可改善早产儿预后,减少或减轻早产儿脑损伤。
Objective To investigate the role of erythropoietin (EPO) in prevention and treatment of brain injury in premature infants. Methods 30 cases of premature children. 23 males and 7 females were randomly divided into routine treatment group and EPO treatment group, 15 cases each. EPO treatment group started EPO treatment after birth. All patients were followed up to 1 year old. EEG, ABR and B-ultrasound were performed on a regular basis. Neonatal behavioral nerve test (NBNA) was performed at 40 weeks of gestation. Results 1. The NBN score of EPO group was 73.33%, which was significantly higher than that of routine treatment group (26.67%) (P <0.05). 2. Correction of abnormal ABR in children with EPO at 1 month There was no significant difference in the rate of ABR between the two groups (P> 0.05). After 3 to 6 months of follow-up, the abnormal rate of ABR in EPO group was significantly lower than that in routine treatment group (P <0.05). In the later period of EPO, the abnormality of ABR was obviously relieved. Conclusion Early use of EPO can improve the prognosis of preterm children and reduce or alleviate the brain injury in preterm infants.